Literature DB >> 21083342

DBS sampling can be used to stabilize prodrugs in drug discovery rodent studies without the addition of esterase inhibitors.

Celia J D'Arienzo1, Qin C Ji, Lorell Discenza, Georgia Cornelius, John Hynes, Lyndon Cornelius, Joseph B Santella, Timothy Olah.   

Abstract

BACKGROUND: Prodrugs that exhibit ex vivo instability owing to high levels of esterases in rodent blood, plasma and serum present challenges in the accurate determination of drug exposure in samples from pharmacokinetic, pharmacokinetic/pharmacodynamic, efficacy and toxicology studies in drug discovery. Ensuring the stability of analytes in sample collection, handling, analysis and storage must be established for program progression. Current protocols for the stabilization of prodrugs include the immediate quenching of whole blood with acetonitrile or methanol to stop enzyme activity, or the addition of an esterase inhibitor such as phenylmethanesulfonyl fluoride to the blood collection tubes before serum or plasma is generated. Dried blood spots (DBS) sampling may offer an alternative prodrug stabilization method for sample collection and storage from rodent studies in drug discovery.
RESULTS: Two different prodrugs of the same parent compound that were known to exhibit ex vivo instability in rodent blood were selected for the evaluation of DBS for analyte stabilization. Each prodrug was spiked separately into fresh rat EDTA whole blood and prepared three ways: from liquid whole blood, prepared and analyzed as lysate; from whole blood spotted onto Whatman 903(®) Protein Saver untreated cards (903 cards); and from whole blood spotted onto Whatman FTA(®) Elute Micro treated cards, currently known as DMPK-B cards (FTA cards). Samples were extracted by filtration-assisted protein precipitation at 0, 2, 5 and 24 h and 4, 7, 14 and 21 days after spiking and analyzed by UHPLC-MS/MS.
CONCLUSIONS: For these two prodrugs, stability on DBS cards was observed in rat EDTA whole blood for at least 21 days at room temperature as determined by loss of prodrug and appearance of parent. The Whatman FTA Elute cards, treated with reagents that lyse cells, did not offer more stability for the investigated compounds than the Whatman 903 Protein Saver untreated cards.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 21083342     DOI: 10.4155/bio.10.94

Source DB:  PubMed          Journal:  Bioanalysis        ISSN: 1757-6180            Impact factor:   2.681


  5 in total

Review 1.  Alternative Sampling Strategies for Cytochrome P450 Phenotyping.

Authors:  Pieter M M De Kesel; Willy E Lambert; Christophe P Stove
Journal:  Clin Pharmacokinet       Date:  2016-02       Impact factor: 6.447

2.  Implementing dried blood spot sampling for clinical pharmacokinetic determinations: considerations from the IQ Consortium Microsampling Working Group.

Authors:  Christopher Evans; Mark Arnold; Peter Bryan; Jeffrey Duggan; Christopher A James; Wenkui Li; Steve Lowes; Luca Matassa; Timothy Olah; Philip Timmerman; Xiaomin Wang; Enaksha Wickremsinhe; John Williams; Eric Woolf; Patricia Zane
Journal:  AAPS J       Date:  2014-12-09       Impact factor: 4.009

Review 3.  Therapeutic drug monitoring by dried blood spot: progress to date and future directions.

Authors:  Abraham J Wilhelm; Jeroen C G den Burger; Eleonora L Swart
Journal:  Clin Pharmacokinet       Date:  2014-11       Impact factor: 6.447

4.  Dried blood spot UHPLC-MS/MS analysis of oseltamivir and oseltamivircarboxylate--a validated assay for the clinic.

Authors:  Gero P Hooff; Roland J W Meesters; Jeroen J A van Kampen; Nick A van Huizen; Birgit Koch; Asmar F Y Al Hadithy; Teun van Gelder; Albert D M E Osterhaus; Rob A Gruters; Theo M Luider
Journal:  Anal Bioanal Chem       Date:  2011-05-03       Impact factor: 4.142

5.  Advantages and Challenges of Dried Blood Spot Analysis by Mass Spectrometry Across the Total Testing Process.

Authors:  Rosita Zakaria; Katrina J Allen; Jennifer J Koplin; Peter Roche; Ronda F Greaves
Journal:  EJIFCC       Date:  2016-12-01
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.